L. Mutualité-française, Rapport 2012 sur les médicaments génériques [Internet]. [cité 29 juill 2013]. Disponible sur: http://www.medicamentsgeneriques, pp.2012-2024, 2009.

H. Bagheri, Points sur les médicaments génériques [Internet]. [cité 29 juill 2013, Disponible sur

L. Maladie, Avenant n°1 à l'accord local du 21 février 2007 relatif à la délivrance des médicaments génériques

L. Maladie, Dispositif tiers payant contre générique Quelle facturation pour le pharmacien?

S. Canada, Médicaments et produits de santé [Internet]. [cité 29 juill 2013]. Disponible sur: http://www.hc-sc.gc.ca/dhp-mps

G. Canada, Article C.08.002.1 Règlement sur les aliments et drogues [Internet]. 2013 [cité 29 juill 2013]. Disponible sur: http://lawslois .justice.gc.ca, %2C_ch._870, pp.296-309

. Ordre-des-pharmaciens-du-québec, Role 6: Gérer les médicaments.pdf [Internet]. [cité 29 juill 2013]. Disponible sur: http://guide.opq.org

V. Debat, ANalysis Of Variance [Internet]. [cité 30 juill 2013, Disponible sur

R. L. Verbeeck and . Bioéquivalence, Disponible sur: http://www.gbs-vbs.org/lms, pp.402-406, 2013.

J. Desmeules, Les médicaments génériques: panacée ou illusion? Pharma-Flash, p.1, 2003.

F. Guzman, Therapeutic index, CME at Pharmacology Corner

H. Blix, K. Viktil, T. Moger, and A. Reikvam, Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharmacy Practice, pp.50-55, 2010.

C. Research and . De, Development & Approval Process (Drugs) -Orange Book Preface

M. L. Mallaret and . Génériques, Mythes et réalités, 2012.

A. Van-der-meersch, A. Dechartres, and P. Ravaud, Quality of Reporting of Bioequivalence Trials Comparing Generic to Brand Name Drugs: A Methodological Systematic Review, PLoS ONE, vol.24, issue.8, p.23611, 2011.
DOI : 10.1371/journal.pone.0023611.s008

B. Davit, P. Nwakama, G. Buehler, D. Conner, S. Haidar et al., Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration, Annals of Pharmacotherapy, vol.84, issue.9, pp.1583-1597, 2009.
DOI : 10.1345/aph.1M141

S. Rohilla, A. Rohilla, and A. Nanda, Biowaivers: Criteria and Requirements, International Journal of Pharmaceutical & Biological Archives, vol.3723, issue.4, pp.727-731487, 2012.

F. Guidance and . Industry, Waiver of In Vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System Disponible sur: http://www.fda.gov Biopharmaceutics Classification System and formulation development, Internet]. [cité 30 juill 2013Guidances/ucm070246.pdf 58 Disponible sur, p.2011, 2000.

M. Lindenberg, S. Kopp, and J. Dressman, Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system, European Journal of Pharmaceutics and Biopharmaceutics, vol.58, issue.2, pp.265-278, 2004.
DOI : 10.1016/j.ejpb.2004.03.001

A. Gougoux, La physiologie du rein et des liquides corporels, Gaetan Morin

S. Querin and L. Valiquette, L'essentiel sur la néphrologie et l'urologie. 2ieme éd. Maloine

L. Grande, Edition 1971-1976, p.10646, 10646.

A. Française-d-'urologie, La transplantation rénale [Internet]. [cité 22 août 2013] Disponible sur: http://www.urofrance.org/fileadmin, 2010.

L. Agence-de and . Biomédecine, Rapport annuel, 2011.

L. Agence-de and . Biomédecine, Synthèse de l'activité régionale de prélèvement et de greffe en Rhône-Alpes, 2010.

S. Française-de-transplantation, Texte d'information sur la greffe rénale destiné aux adultes et aux enfants, 1999.

. Groupe-de-travail-de-la-société-de-néphrologie, [Evaluation of glomerular filtration rate and proteinuria for the diagnosis of chronic kidney disease]. Néphrologie Thérapeutique, juill, vol.5, issue.4, pp.302-305, 2009.

L. Balssa, H. Bittard, and F. Kleinclauss, Immunosuppression en transplantation r??nale, Progr??s en Urologie, vol.21, issue.4, pp.250-253, 2011.
DOI : 10.1016/j.purol.2010.08.048

C. Legendre and E. Thervet, La pharmacologie des immunosuppresseurs actuels. Médecine Thérapeutique. 3 mars 1999, pp.101-108

E. Thervet, J. Zuber, R. Sberro, G. Canaud, D. Anglicheau et al., Immunosuppressive treatments: mechanisms of action and clinical use]. Néphrologie Thérapeutique, déc, vol.7, issue.7, pp.566-581, 2011.

C. Loichot and . Les, Disponible sur: http://www-ulpmed.ustrasbg.fr/medecine, 2013.

P. Halloran, Immunosuppressive Drugs for Kidney Transplantation, New England Journal of Medicine, vol.351, issue.26, pp.2715-2729, 2004.
DOI : 10.1056/NEJMra033540

B. Kasiske, M. Vazquez, W. Harmon, R. Brown, G. Danovitch et al., Recommendations for the Outpatient Surveillance of Renal Transplant Recipients, J Am Soc Nephrol. 10 janv, vol.11, issue.1, pp.1-86, 2000.

P. Marquet, Suivi th??rapeutique pharmacologique pour l???adaptation de posologie des m??dicaments, Le Pharmacien Hospitalier, vol.43, issue.173, 2004.
DOI : 10.1016/S0768-9179(08)70010-5

P. Wallemacq, V. Armstrong, M. Brunet, V. Haufroid, D. Holt et al., Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Therapeutic Drug Monitoring, vol.31, issue.2, pp.139-152, 2009.
DOI : 10.1097/FTD.0b013e318198d092

H. Commission-de-la-transparence, Avis du 16 juillet Rapamune [Internet]. [cité 3 sept 2013, Disponible sur, 2008.

T. Van-gelder, L. Meur, Y. Shaw, L. Oellerich, M. Denofrio et al., Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation, Therapeutic Drug Monitoring, vol.28, issue.2
DOI : 10.1097/01.ftd.0000199358.80013.bd

S. Knight and P. Morris, Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review, Transplantation, vol.85, issue.12, pp.1675-1685, 2008.
DOI : 10.1097/TP.0b013e3181744199

T. Van-gelder, L. Hilbrands, Y. Vanrenterghem, W. Weimar, J. De-fijter et al., A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation, Transplantation. 27 juill, vol.68, issue.2, pp.261-266, 1999.

A. Cilia, N. Costa, A. Durand, and P. Pisano, Intérêt du suivi thérapeutique du mycophénolate mofétil, Lett Pharmacol, vol.16, issue.1, pp.5-11

L. Meur, Y. Büchler, M. Thierry, A. Caillard, S. Villemain et al., Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, American Journal of Transplantation, vol.82, issue.1, pp.2496-2503, 2007.
DOI : 10.1097/00007691-200412000-00005

E. David-neto, L. Pereira, E. Kakehashi, N. Sumita, M. Mendes et al., The need of mycophenolic acid monitoring in long-term renal transplants, Clinical Transplantation, vol.48, issue.1, pp.19-25, 2005.
DOI : 10.1093/ndt/14.suppl_4.33

L. Shaw, M. Figurski, M. Milone, J. Trofe, and R. Bloom, Therapeutic Drug Monitoring of Mycophenolic Acid, Clinical Journal of the American Society of Nephrology, vol.2, issue.5, pp.1062-1072, 2007.
DOI : 10.2215/CJN.03861106

C. Coursol, La substitution générique présente-t-elle un danger chez le patient greffé?

B. Crowther, The Skinny on Narrow Therapeutic Index Drugs Used in Transplantation: A Brand vs. Generic Debate

L. Meur, Y. Sebbag, L. Anglicheau, D. Kamar, N. Billaud et al., SFT - Recommandation de la SFT sur l'utilisation des génériques des immunosuppresseurs. - Actualités: site de la SFT

R. Therrien and T. Sastre, Pharmacocinétique du mofétilmycophénolate en greffe hématopoïétique: étude d'un cas pédiatrique, p.2, 2008.

J. Aiache, J. Besner, P. Buri, P. Blanc, and M. Lesne, Traité de biopharmacie et pharmacocinétique. Vigot, 1985.

S. Patel, V. Chauhan, J. Mandal, S. Shah, K. Patel et al., Single-dose, Two-way Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects, Clinical Therapeutics, vol.33, issue.3, pp.378-390, 2011.
DOI : 10.1016/j.clinthera.2011.04.003

Q. Zhang, Y. Tao, Y. Zhu, and D. Zhu, Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, two-way crossover study, Clinical Therapeutics, vol.32, issue.1, pp.171-178, 2010.
DOI : 10.1016/j.clinthera.2010.01.013

M. Masri, S. Rizk, M. Attia, H. Barbouch, and M. Rost, Bioavailability of a New Generic Formulation of Mycophenolate Mofetil MMF 500 Versus CellCept in Healthy Adult Volunteers, Transplantation Proceedings, vol.39, issue.4, pp.1233-1236, 2007.
DOI : 10.1016/j.transproceed.2007.03.055

M. Masri, T. Andrysek, S. Rizk, and M. V. , The role of generics in transplantation: TM-MMF versus cellcept in healthy volunteers, Transplantation Proceedings, vol.36, issue.1, pp.84-85, 2004.
DOI : 10.1016/j.transproceed.2003.11.008

S. Almeida, F. A. Neves, R. Spínola, A. Tanguay, M. Ortuño et al., Mycophenolate mofetil 500-mg tablet under fasting conditions: Single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects, Clinical Therapeutics, vol.32, issue.3, pp.556-574, 2010.
DOI : 10.1016/j.clinthera.2010.03.008

T. Abdallah, M. Ounissi, M. Cherif, I. Helal, C. Karoui et al., The role of generics in kidney transplant: mycophenolate mofetil 500 versus mycophenolate: 2-year results, Exp Clin Transplant Off J Middle East Soc Organ Transplant. déc, vol.8, issue.4, pp.292-296, 2010.

B. Rutkowski, B. Bzoma, A. D?bska-?lizie?, and A. Chamienia, Immunosuppressive regimens containing generic mycophenolate mofetil (Myfenax) in de novo renal transplant recipients ??? preliminary results of 6-month observation, Annals of Transplantation, vol.16, issue.4, pp.74-80, 2011.
DOI : 10.12659/AOT.882222

H. Müller, S. Solari, C. Zuñiga, C. Pedreros, J. Troncoso et al., Immunosuppression With Generic Tacrolimus and Mycophenolate Mofetil in Renal Transplant Recipients: Preliminary Report in Chile, Transplantation Proceedings, vol.40, issue.3, pp.705-707, 2008.
DOI : 10.1016/j.transproceed.2008.02.056

C. Videla and C. Godoy, Converting to a Generic Formulation of Mycophenolate Mofetil in Stable Kidney Transplant Recipients: 1 Year of Drug Surveillance and Outcome, Transplantation Proceedings, vol.39, issue.3, pp.602-605, 2007.
DOI : 10.1016/j.transproceed.2006.12.034

G. Sunder-plassmann, P. Reinke, T. Rath, A. Wiecek, M. Nowicki et al., Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients, Transplant International, vol.23, issue.115, pp.680-686, 2012.
DOI : 10.1111/j.1432-2277.2012.01475.x

T. Marsen, How Safe Is Conversion from Tacrolimus to Its Generic Drug????A Single Center Experience, Open Journal of Nephrology, vol.02, issue.04, pp.72-77, 2012.
DOI : 10.4236/ojneph.2012.24012

J. Momper, T. Ridenour, K. Schonder, R. Shapiro, A. Humar et al., The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft Function, American Journal of Transplantation, vol.43, issue.9, pp.1861-1867, 2011.
DOI : 10.1111/j.1600-6143.2011.03615.x

J. Momper, P. Fontes, M. Devera, A. Humar, R. Shapiro et al., Generic substitution of tacrolimus appears to be safe in the short term in clinically stable liver and kidney transplant patients, but monitoring of tacrolimus blood concentrations in individual patients is essentia, Disponible sur, 2013.

H. Abdulnour, C. Araya, and V. Dharnidharka, Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: Brief communication, Pediatric Transplantation, vol.40, issue.Suppl. 115
DOI : 10.1111/j.1399-3046.2010.01393.x

R. Alloway, B. Sadaka, J. Trofe-clark, A. Wiland, and R. Bloom, A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients, American Journal of Transplantation, vol.14, issue.Suppl 2, pp.2825-2831, 2012.
DOI : 10.1111/j.1600-6143.2012.04174.x

Y. Qazi, A. Forrest, K. Tornatore, and R. Venuto, The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function, Clinical Transplantation, vol.5, issue.2, pp.313-317, 2006.
DOI : 10.1016/S0149-2918(03)80161-3

W. Carnahan and T. Cooper, Neoral-to-gengraf conversion in renal transplant recipients, Transplantation Proceedings, vol.35, issue.4, pp.1308-1313, 2003.
DOI : 10.1016/S0041-1345(03)00423-8

A. Roza, S. Tomlanovich, R. Merion, R. Pollak, F. Wright et al., Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation, Transplantation, vol.74, issue.7, pp.1013-1017, 2002.
DOI : 10.1097/00007890-200210150-00020

D. Taber, G. Baillie, E. Ashcraft, R. J. Lin, A. Afzal et al., Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation. 15 déc, pp.1633-1635, 2005.

S. Vítko and M. Ferkl, Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial, Kidney International, vol.77, issue.115, pp.12-16, 2010.
DOI : 10.1038/ki.2009.506

A. Singh and S. Narsipur, Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange, Journal of Transplantation, vol.33, issue.2, p.480642, 2011.
DOI : 10.1046/j.1600-6143.2003.00212.x

A. Olyaei, A. Demattos, and W. Bennett, Switching Between Cyclosporin Formulations What are the Risks?, Drug Safety, vol.16, issue.6, pp.366-373, 1997.
DOI : 10.2165/00002018-199716060-00003

S. Pollard, B. Nashan, A. Johnston, P. Hoyer, P. Belitsky et al., A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A, Clinical Therapeutics, vol.25, issue.6, pp.1654-1669, 2001.
DOI : 10.1016/S0149-2918(03)80161-3

J. Kovarik, A. Noe, Y. Wang, I. Mueller, G. Denucci et al., Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus, European Journal of Clinical Pharmacology, vol.22, issue.Suppl B, pp.361-366, 2006.
DOI : 10.1007/s00228-006-0109-z

. Cour-des-comptes, Rapport 2012 sur l'application des lois de financement de la Sécurité sociale. Cour des comptes, septembre 2012, 1346358.

. Ligue-française-contre-l-'epilepsie, Communiqué de presse 3 juillet Recommandations de la LFCE concernant l'usage des médicaments antiépileptiques génériques chez les patients souffrant d'épilepsie, Communiqu%8E%20de%20Presse%20LFCE, 2007.

A. Academy and . Neurology, Position statement of the coverage of anticonvulsant drugs for the treatment of epilepsy, 2006.

S. Mintzer, Brand Spanking? The Presumptive Risks of Generic Antiepileptic Drugs, Epilepsy Currents, vol.11, issue.2, pp.54-55, 2011.
DOI : 10.5698/1535-7511-11.2.54

S. Chaluvadi, S. Chiang, L. Tran, C. Goldsmith, and D. Friedman, Clinical experience with generic levetiracetam in people with epilepsy, Epilepsia, vol.71, issue.4, pp.810-815, 2011.
DOI : 10.1111/j.1528-1167.2011.03025.x

M. Berg, R. Gross, K. Tomaszewski, W. Zingaro, and L. Haskins, Generic substitution in the treatment of epilepsy: Case evidence of breakthrough seizures, Neurology, vol.71, issue.7, pp.525-530, 2008.
DOI : 10.1212/01.wnl.0000319958.37502.8e

C. Fitzgerald and M. Jacobson, Generic Substitution of Levetiracetam Resulting in Increased Incidence of Breakthrough Seizures, Annals of Pharmacotherapy, vol.45, issue.5, p.27, 2011.
DOI : 10.1345/aph.1P765

K. Makus and J. Mccormick, Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy, Clinical Therapeutics, vol.29, issue.2, pp.334-341, 2007.
DOI : 10.1016/j.clinthera.2007.02.005

S. Kinikar, T. Delate, C. Menaker-wiener, and W. Bentley, Clinical Outcomes Associated with Brand-to-Generic Phenytoin Interchange, Annals of Pharmacotherapy, vol.4, issue.5, pp.650-658, 2012.
DOI : 10.1345/aph.1Q601

T. Buck, A. Schmedes, and I. Brandslund, Does generic lamotrigine lead to larger variations in plasma concentrations?]. Ugeskr Laeger, pp.2013-2015, 2007.

R. Talati, J. Scholle, O. Phung, E. Baker, W. Baker et al., Efficacy and Safety of Innovator versus Generic Drugs in Patients with Epilepsy: A Systematic Review, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol.43, issue.3, pp.314-322, 2012.
DOI : 10.1002/j.1875-9114.2012.01099.x

M. Yamada and T. Welty, Generic Substitution of Antiepileptic Drugs: A Systematic Review of Prospective and Retrospective Studies, Annals of Pharmacotherapy, vol.39, issue.11, pp.1406-1415, 2011.
DOI : 10.1345/aph.1Q349

D. Hartung, L. Middleton, L. Svoboda, and J. Mcgregor, Generic Substitution of Lamotrigine Among Medicaid Patients with Diverse Indications, CNS Drugs, vol.21, issue.8, pp.707-716, 2012.
DOI : 10.2165/11634260-000000000-00000

A. Kesselheim, M. Stedman, E. Bubrick, J. Gagne, A. Misono et al., Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs, Drugs, vol.14, issue.1, pp.605-621, 2010.
DOI : 10.2165/10898530-000000000-00000

. Commission-nationale-de-pharmacovigilance, Compte rendu de la réunion du mardi 27 mars 2012

B. Dong and C. Brown, Hypothyroidism resulting from generic levothyroxine failure. J Am Board Fam Pr Am Board Fam Pr, juin, vol.4, issue.3, pp.167-170, 1991.

V. Bagouet and . Apm-international-l-', ANSM a demandé à Merck Serono une adaptation de la teneur en principe actif de Levothyrox

A. Nationale-de-médecine, Pénurie de Levothyrox, Communiqué du 17 aout 2013

J. Lomenick, L. Wang, S. Ampah, B. Saville, and F. Greenwald, Generic Levothyroxine Compared With Synthroid in Young Children With Congenital Hypothyroidism, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.2, pp.653-658, 2013.
DOI : 10.1210/jc.2012-3558

J. Carswell, J. Gordon, E. Popovsky, A. Hale, and R. Brown, -Thyroxine Are Not Bioequivalent for Children With Severe Congenital Hypothyroidism, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.2, pp.610-617, 2013.
DOI : 10.1210/jc.2012-3125

S. Bolton, Bioequivalence studies for levothyroxine, The AAPS Journal, vol.7, issue.1, pp.47-53, 2005.
DOI : 10.1208/aapsj070106

M. Gibaldi, Bioequivalence of thyroid preparations: The final word?, The AAPS Journal, vol.7, issue.1, pp.59-60, 2005.
DOI : 10.1208/aapsj070108

V. Blakesley, W. Awni, C. Locke, T. Ludden, G. Granneman et al., Are Bioequivalence Studies of Levothyroxine Sodium Formulations in Euthyroid Volunteers Reliable?, Thyroid, vol.14, issue.3, pp.191-200, 2004.
DOI : 10.1089/105072504773297867

O. Vesga, M. Agudelo, B. Salazar, C. Rodriguez, and A. Zuluaga, Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator, Antimicrobial Agents and Chemotherapy, vol.54, issue.8
DOI : 10.1128/AAC.01044-09

P. Tattevin, A. Saleh-mghir, B. Davido, I. Ghout, L. Massias et al., Comparison of Six Generic Vancomycin Products for Treatment of Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis in Rabbits, Antimicrobial Agents and Chemotherapy, vol.57, issue.3, pp.1157-1162, 2013.
DOI : 10.1128/AAC.01669-12

M. Hadwiger, C. Sommers, D. Mans, V. Patel, and M. Boyne, Quality Assessment of U.S. Marketplace Vancomycin for Injection Products Using High-Resolution Liquid Chromatography-Mass Spectrometry and Potency Assays, Antimicrobial Agents and Chemotherapy, vol.56, issue.6, pp.2824-2830, 2012.
DOI : 10.1128/AAC.00164-12

C. Rodriguez, M. Agudelo, J. Cataño, A. Zuluaga, and O. Vesga, Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia, Journal of Infection, vol.59, issue.4, pp.277-280, 2009.
DOI : 10.1016/j.jinf.2009.08.005

S. Fujimura, K. Fuse, H. Takane, Y. Nakano, K. Gomi et al., Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus, Journal of Infection and Chemotherapy, vol.17, issue.1, pp.30-33, 2011.
DOI : 10.1007/s10156-010-0094-0

A. Zuluaga, M. Agudelo, C. Rodriguez, and O. Vesga, Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics, BMC Clinical Pharmacology, vol.38, issue.1, 2009.
DOI : 10.7164/antibiotics.38.51

R. Haynes and D. Sackett, Compliance in Health Care, 1979.

M. Baudrant-boga, A. Lehmann, and B. Allenet, Penser autrement l???observance m??dicamenteuse??: d???une posture injonctive ?? une alliance th??rapeutique entre le patient et le soignant ??? Concepts et d??terminants, Annales Pharmaceutiques Fran??aises, vol.70, issue.1, pp.15-25, 2012.
DOI : 10.1016/j.pharma.2011.10.003

A. Lamouroux, A. Magnan, and D. Vervloet, Compliance, observance ou adh??sion th??rapeutique : de quoi parlons-nous ?, Revue des Maladies Respiratoires, vol.22, issue.1, pp.31-34, 2005.
DOI : 10.1016/S0761-8425(05)85433-6

L. Osterberg and T. Blaschke, Adherence to Medication, New England Journal of Medicine, vol.353, issue.5, pp.487-497, 2005.
DOI : 10.1056/NEJMra050100

M. Dew, A. Dimartini, D. V. Dabbs, A. Myaskovsky, L. Steel et al., Rates and Risk Factors for Nonadherence to the Medical Regimen After Adult Solid Organ Transplantation, Transplantation, vol.83, issue.7, pp.858-873, 2007.
DOI : 10.1097/01.tp.0000258599.65257.a6

P. Burra, G. Germani, F. Gnoato, S. Lazzaro, F. Russo et al., Adherence in liver transplant recipients. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc, juill, vol.17, issue.7, pp.760-770, 2011.

M. Dew, A. Dimartini, D. V. Dabbs, A. Zomak, R. et al., Adherence to the Medical Regimen During the First Two Years After Lung Transplantation, Transplantation, vol.85, issue.2, pp.193-202, 2008.
DOI : 10.1097/TP.0b013e318160135f

D. Geest, S. Dobbels, F. Fluri, C. Paris, W. Troosters et al., Adherence to the Therapeutic Regimen in Heart, Lung, and Heart-Lung Transplant Recipients, The Journal of Cardiovascular Nursing, vol.20, issue.Supplement, pp.88-98, 2005.
DOI : 10.1097/00005082-200509001-00010

O. Brien, R. Aslani, P. Ciccia, M. Brien, and J. , Medication adherence among heart and/or lung transplant recipients: An exploratory study, Patient Prefer Adherence, vol.2, pp.115-120, 2008.

V. Korb-savoldelli, B. Sabatier, F. Gillaizeau, R. Guillemain, P. Prognon et al., Non-adherence with drug treatment after heart or lung transplantation in adults: A systematic review, Patient Education and Counseling, vol.81, issue.2, pp.148-154, 2010.
DOI : 10.1016/j.pec.2010.04.013

G. Germani, S. Lazzaro, F. Gnoato, M. Senzolo, V. Borella et al., Nonadherent Behaviors After Solid Organ Transplantation, Transplantation Proceedings, vol.43, issue.1, pp.318-323, 2011.
DOI : 10.1016/j.transproceed.2010.09.103

M. Chisholm-burns, B. Pinsky, G. Parker, P. Johnson, S. Arcona et al., Factors related to immunosuppressant medication adherence in renal transplant recipients, Clinical Transplantation, vol.31, issue.5, pp.706-713, 2012.
DOI : 10.1111/j.1399-0012.2011.01589.x

D. Kuypers, P. Peeters, J. Sennesael, M. Kianda, B. Vrijens et al., Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients, Transplantation Journal, vol.95, issue.2, pp.333-340, 2013.
DOI : 10.1097/TP.0b013e3182725532

S. Terebelo and M. Markell, Preferential Adherence to Immunosuppressive Over Nonimmunosuppressive Medications in Kidney Transplant Recipients, Transplantation Proceedings, vol.42, issue.9, pp.3578-3585, 2010.
DOI : 10.1016/j.transproceed.2010.08.027

J. Sankaranarayanan, D. Collier, A. Furasek, T. Reardon, L. Smith et al., Rurality and other factors associated with adherence to immunosuppressant medications in community-dwelling solid-organ transplant recipients, Research in Social and Administrative Pharmacy, vol.8, issue.3, pp.228-239, 2012.
DOI : 10.1016/j.sapharm.2011.04.001

F. Ortega, A. Otero, J. Crespo, J. Delgado, J. Borro et al., Satisfaction and adherence with immunosuppressant treatment in renal transplant patients living with a working graft, Journal of Nephrology, vol.26, issue.2, pp.297-305, 2013.
DOI : 10.5301/jn.5000132

O. Suárez, F. , S. Plumed, J. , P. Valentín et al., Validation on the simplified medication adherence questionnaire (SMAQ) in renal transplant patients on tacrolimus, Nefrol Publicación Of Soc Española Nefrol, vol.31, issue.6, pp.690-696, 2011.

C. Ponticelli and G. Graziani, Education and counseling of renal transplant recipients, Journal of Nephrology, vol.25, issue.6, pp.879-889, 2012.
DOI : 10.5301/jn.5000227

D. Bleser, L. Dobbels, F. Berben, L. Vanhaecke, J. Verleden et al., The spectrum of nonadherence with medication in heart, liver, and lung tranplant patients assessed in various ways, Transplant International, vol.17, issue.9, pp.882-91, 2011.
DOI : 10.1111/j.1432-2277.2011.01296.x

M. Dew, A. Dimartini, D. V. Dabbs, A. Myaskovsky, L. Steel et al., Rates and Risk Factors for Nonadherence to the Medical Regimen After Adult Solid Organ Transplantation, Transplantation, vol.83, issue.7, pp.858-873, 2007.
DOI : 10.1097/01.tp.0000258599.65257.a6

K. Denhaerynck, F. Dobbels, I. Cleemput, A. Desmyttere, P. Schäfer-keller et al., Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review, Transplant International, vol.5, issue.10, pp.1121-1133, 2005.
DOI : 10.1097/00007890-200010270-00020

E. Sabate, Adherence to long-term therapies: Evidence for action [Internet]. [cité 21 sept 2013, Disponible sur, 2003.

A. Hugon, Prédire l'adhésion aux traitements immunosuppresseurs chez le patient transplanté : étude PrATIS. 26 sept 2011 [cité 21 sept 2013]; Disponible sur

A. Hulbert, N. Pilch, D. Taber, K. Chavin, and P. Baliga, Generic Immunosuppression: Deciphering the Message Our Patients are Receiving, Annals of Pharmacotherapy, vol.56, issue.5, pp.671-677, 2012.
DOI : 10.1345/aph.1R028

A. Ameri, M. Whittaker, C. Tucker, A. Yaqoob, M. Johnston et al., A survey to determine the views of renal transplant patients on generic substitution in the UK, Transplant International, vol.332, issue.8, pp.770-779, 2011.
DOI : 10.1111/j.1432-2277.2011.01268.x

A. Ameri, M. , M. W. Makramalla, E. Shalhoub, B. Tucker et al., Renal patients' views on generic prescribing and substitution: example from the United Arab Emirates. East Mediterr Heal J Rev Santé Méditerranée Orient Al-Majallah Al- S.h.H?yah Li-Sharq Al-Mutawassit, avr, vol.19, issue.4, pp.373-381, 2013.

K. Parker, E. Zagadailov, A. Bruno, and A. Wiland, Transplant Coordinators' Perceived Impact of Availability of Multiple Generic Immunosuppression Therapies on Patients, Workload, and Posttransplant Maintenance Therapy, Journal of Transplantation, vol.1, issue.1, 2013.
DOI : 10.2215/CJN.01630210

J. Harrison, J. Schiff, C. Coursol, C. Daley, A. Dipchand et al., Generic Immunosuppression in Solid Organ Transplantation, Transplantation, vol.93, issue.7, pp.657-665, 2012.
DOI : 10.1097/TP.0b013e3182445e9d

B. Allenet and A. Golay, What are patients' attitudes towards generic drugs? The example of metformin]. Rev Médicale Suisse, pp.1005-1009, 2013.

W. Shrank, T. Hoang, S. Ettner, P. Glassman, K. Nair et al., The Implications of Choice, Archives of Internal Medicine, vol.166, issue.3, pp.332-337, 2006.
DOI : 10.1001/archinte.166.3.332

J. Rathe, P. Larsen, M. Andersen, M. Paulsen, D. Jarbøl et al., Associations between generic substitution and patients' attitudes, beliefs and experiences, European Journal of Clinical Pharmacology, vol.28, issue.5, 2013.
DOI : 10.1007/s00228-013-1539-z

T. Janse-de-hoog, Interchangeability of generics [Internet]. [cité 29 août 2013] Disponible sur

H. Håkonsen, M. Eilertsen, H. Borge, and E. Toverud, Generic substitution: additional challenge for adherence in hypertensive patients?, Current Medical Research and Opinion, vol.25, issue.10, pp.2515-2521, 2009.
DOI : 10.1185/03007990903192223

H. Håkonsen and E. Toverud, Special challenges for drug adherence following generic substitution in Pakistani immigrants living in Norway, European Journal of Clinical Pharmacology, vol.65, issue.2, pp.193-201, 2011.
DOI : 10.1007/s00228-010-0960-9

W. Himmel, A. Simmenroth-nayda, W. Niebling, T. Ledig, R. Jansen et al., What do primary care patients think about generic drugs?, Int. Journal of Clinical Pharmacology and Therapeutics, vol.43, issue.10, pp.472-479, 2005.
DOI : 10.5414/CPP43472

M. Pruszydlo, R. Quinzler, J. Kaltschmidt, and W. Haefeli, Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany

A. Kesselheim, A. Misono, W. Shrank, J. Greene, M. Doherty et al., Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence, JAMA Internal Medicine, vol.173, issue.3, pp.202-208, 2013.
DOI : 10.1001/2013.jamainternmed.997

M. Figueiras, N. Alves, D. Marcelino, M. Cortes, J. Weinman et al., Assessing lay beliefs about generic medicines: Development of the generic medicines scale, Psychology, Health & Medicine, vol.10, issue.3, pp.311-321, 2009.
DOI : 10.1016/S0212-6567(05)70550-3

S. Ngo, I. Stupans, and R. Mckinnon, Generic substitution in the treatment of epilepsy: Patient attitudes and perceptions, Epilepsy & Behavior, vol.26, issue.1, pp.64-66, 2013.
DOI : 10.1016/j.yebeh.2012.10.032

J. Weissenfeld, S. Stock, M. Lüngen, and A. Gerber, The nocebo effect: a reason for patients' non-adherence to generic substitution? Pharm, juill, vol.65, issue.7, pp.451-456, 2010.

L. Entreprises and D. Médicament, Les génériques sont-ils un facteur d'économies pour l'Assurance Maladie? Fiche 65

R. Lesur, Le médicament générique: des attentes à la réalité, Réalités Ind. (FEV, pp.66-68

K. Hadaya, Les génériques en immunosuppression, Disponible sur, pp.3-9, 2012.

C. Cutler, A. Kesselheim, S. Gabardi, B. Andersson, P. Carpenter et al., Generic Immunosuppressants in Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.17, issue.3, pp.285-290, 2011.
DOI : 10.1016/j.bbmt.2010.11.006

J. Helderman, N. Kang, A. Legorreta, and J. Chen, Healthcare costs in renal transplant recipients using branded versus generic ciclosporin, Applied Health Economics and Health Policy, vol.38, issue.7, pp.61-68, 2010.
DOI : 10.1007/BF03256166

J. Gilman, L. Alvarez, and M. Duchowny, Carbamazepine toxicity resulting from generic substitution, Neurology, vol.43, issue.12, pp.2696-2697, 1993.
DOI : 10.1212/WNL.43.12.2696

M. Duh, F. Andermann, P. Paradis, J. Weiner, R. Manjunath et al., The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine, Disease Management, vol.10, issue.4, pp.216-225, 2007.
DOI : 10.1089/dis.2007.104649

M. Duh, P. Paradis, D. Latrémouille-viau, P. Greenberg, S. Lee et al., The risks and costs of multiple-generic substitution of topiramate, Neurology, vol.72, issue.24, pp.2122-2129, 2009.
DOI : 10.1212/WNL.0b013e3181aa5300

P. Paradis, D. Latrémouille-viau, Y. Moore, N. Mishagina, M. Lafeuille et al., Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries, Current Medical Research and Opinion, vol.25, issue.7, pp.1793-1805, 2009.
DOI : 10.1185/03007990903044374

J. Lelorier, M. Duh, P. Paradis, D. Latrémouille-viau, P. Lefebvre et al., Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting, Current Medical Research and Opinion, vol.24, issue.4, pp.1069-1081, 2008.
DOI : 10.1185/030079908X280572

S. Helmers, P. Paradis, R. Manjunath, M. Duh, M. Lafeuille et al., Economic burden associated with the use of generic antiepileptic drugs in the United States, Epilepsy & Behavior, vol.18, issue.4, pp.437-444, 2010.
DOI : 10.1016/j.yebeh.2010.05.015

. Académie-nationale-de-pharmacie, Rapport de l'Académie nationale de Pharmacie sur les médicaments génériques du 24 Octobre 2012

S. Suisse-de-transplantation, Utilisation de médicaments génériques pour l'immunosuppression après greffe d'organes [Internet]. [cité 10 sept 2013, Disponible sur

R. Alloway, R. Isaacs, K. Lake, P. Hoyer, R. First et al., Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants, American Journal of Transplantation, vol.37, issue.3, pp.1211-1215, 2003.
DOI : 10.1001/jama.283.18.2445

S. Sabatini, R. Ferguson, J. Helderman, A. Hull, B. Kirkpatrick et al., Drug substitution in transplantation: A National Kidney Foundation white paper, American Journal of Kidney Diseases, vol.33, issue.2, pp.389-397, 1999.
DOI : 10.1016/S0272-6386(99)70318-5

P. Uber, H. Ross, A. Zuckermann, S. Sweet, P. Corris et al., Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory, The Journal of Heart and Lung Transplantation, vol.28, issue.7, pp.655-660, 2009.
DOI : 10.1016/j.healun.2009.05.001

M. Deierhoi and M. Haug, Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy, Clinical Transplantation, vol.19, issue.5, pp.439-448, 2000.
DOI : 10.1016/S0041-1345(98)00408-4

T. Schroeder, S. Hariharan, and M. First, Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations, Transplant Proc. févr, vol.27, issue.1, pp.837-839, 1995.

C. Cutler, A. Kesselheim, S. Gabardi, B. Andersson, P. Carpenter et al., Generic Immunosuppressants in Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.17, issue.3, pp.285-290, 2011.
DOI : 10.1016/j.bbmt.2010.11.006